Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

CCL2 mediates anti-fibrotic effects in human fibroblasts independently of CCR2.

Kalderén C, Stadler C, Forsgren M, Kvastad L, Johansson E, Sydow-Bäckman M, Svensson Gelius S.

Int Immunopharmacol. 2014 May;20(1):66-73. doi: 10.1016/j.intimp.2014.02.020. Epub 2014 Feb 26.

PMID:
24583146
2.

Effect of a novel non-thiazolidinedione peroxisome proliferator-activated receptor alpha/gamma agonist on glucose uptake.

Hu X, Feng Y, Liu X, Zhao XF, Yu JH, Yang YS, Sydow-Bäckman M, Hörling J, Zierath JR, Leng Y.

Diabetologia. 2007 May;50(5):1048-57. Epub 2007 Mar 1.

PMID:
17333104
3.

A new class of peroxisome proliferator-activated receptor agonists with a novel binding epitope shows antidiabetic effects.

Ostberg T, Svensson S, Selén G, Uppenberg J, Thor M, Sundbom M, Sydow-Bäckman M, Gustavsson AL, Jendeberg L.

J Biol Chem. 2004 Sep 24;279(39):41124-30. Epub 2004 Jul 15.

4.

Synthesis and pharmacological evaluation of a new class of peroxisome proliferator-activated receptor modulators.

Thor M, Beierlein K, Dykes G, Gustavsson AL, Heidrich J, Jendeberg L, Lindqvist B, Pegurier C, Roussel P, Slater M, Svensson S, Sydow-Bäckman M, Thornström U, Uppenberg J.

Bioorg Med Chem Lett. 2002 Dec 16;12(24):3565-7.

PMID:
12443777
5.

Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction.

Bertilsson G, Heidrich J, Svensson K, Asman M, Jendeberg L, Sydow-Bäckman M, Ohlsson R, Postlind H, Blomquist P, Berkenstam A.

Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12208-13.

6.

Novel forms of B-domain-deleted recombinant factor VIII molecules. Construction and biochemical characterization.

Lind P, Larsson K, Spira J, Sydow-Bäckman M, Almstedt A, Gray E, Sandberg H.

Eur J Biochem. 1995 Aug 15;232(1):19-27.

Supplemental Content

Loading ...
Support Center